

REMARKS

The foregoing Preliminary Amendment is requested in order to delete the multiple dependent claims and avoid paying the multiple dependent claims fee.


Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Early action on the merits is respectfully requested.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By



William E. Player

Reg. No. 31,409

400 Seventh Street, N.W.
Washington, D.C. 20004-2201
(202) 638-6666

Atty. Docket: P67214US0
Date: November 5, 2001
WEP:jrc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

3. (amended) Use of the method according to claims 1 ~~or 2~~ for evaluating a treatment for Alzheimer's disease.
4. (amended) The method according to claim 1 ~~any of claims 1 to 3~~, wherein a level of nerve growth factor ≥ 4 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.
6. (amended) The method according to claim 1 ~~any of claims 1 to 5~~, wherein said subject is a human.
7. (amended) The method according to claim 1 ~~any of claims 1 to 6~~, wherein nerve growth factor is detected using an immunoassay, bioassay and/or binding assay.
8. (amended) The method according to claim 1 ~~any of claims 1 to 7~~, further comprising comparing a level and/or an activity of nerve growth factor in said sample with a level and/or an activity in a series of samples taken from said subject over a period of time.
9. (amended) The method according to claim 1 ~~any of claims 1 to 8~~, wherein said subject receives a treatment prior to one or more of said sample gatherings.

10. (amended) The method according to claim 1 ~~any of claims 1 to 9~~, wherein said level and/or activity in said samples is determined before and after said treatment of said subject.

11. (amended) The method according to claim 1 ~~any of claims 1 to 10~~, further comprising:

determining a level, or an activity, or both said level and said activity, of a further neurotrophin in a sample taken from cerebrospinal fluid of said subject;

and comparing said level, or said activity, or both said level and said activity, to a reference value representing a known disease or health status;

wherein a varied level, or activity, or both said level and said activity, of said further neurotrophin in said cerebrospinal fluid from said subject relative to said reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

17. (amended) The kit according to claim 14 ~~any of claims 14 to 16~~ further comprising:

(a) at least one reagent which selectively detects a further neurotrophin; and

(b) instructions for diagnosing, or prognosing Alzheimer's disease, or determining increased risk of developing Alzheimer's disease by

(i) detecting a level, or an activity, or both said level and said activity, of said further neurotrophin in a sample taken from cerebrospinal fluid of said subject; and

(ii) diagnosing, or prognosing, or determining whether said subject is at increased risk of developing Alzheimer's disease, wherein a varied level or activity, or both said level and said activity, of said further neurotrophin compared to a reference value representing a known health status,

or a level, or an activity, or both said level and said activity, of said further neurotrophin similar or equal to a reference value representing a known disease status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

20. (amended) The kit according to claim 14 ~~any of claims 14 to 19~~ for use in monitoring a progression of Alzheimer's disease in a subject.
21. (amended) The kit according to claim 14 ~~any of claims 14 to 19~~ for use in monitoring the success or failure of a therapeutic treatment of a subject.